Table 2.
The outcomes of ovarian stimulation in cabergoline-treated and control groups
| Outcome of ovarian stimulation |
Cabergoline
(n=50) |
Control
(n=25) |
P value |
|---|---|---|---|
| Number of gonadotropin ampoules (75 IU/ampoule) | 30.74±12.40 | 31.72±13.49 | 0.76 |
| Duration of stimulation (days) | 9.37±0.60 | 9.75±0.56 | 0.98 |
| Estradiol on HCG day (pg/ml) | 3890±345 | 3980±456 | 0.86 |
| Number of retrieved oocytes | 22.18±4.94 | 21.00±5.36 | 0.35 |
| M II oocytes (%) | 70 | 61 | 0.70 |
| Fertilization rate (%) | 55.41 | 58.91 | 0.67 |
| Route of ART | |||
| Embryo transfer | 30 (60%) | 13 (52%) | 0.77 |
| ZIFT | 13(26%) | 5 (20%) | 0.45 |
| Cycle cancellation | 7 (14%) | 7 (28%) | 0.03 |
| Cycle with frozen embryo (%) | 65% | 31% | 0.001 |
| OHSS | 6 (12.0%) | 9 (36.0%) | 0.001 |
| Mild | 2 (4%) | 6 (24%) | 0.001 |
| Moderate | 3 (6%) | 2 (8%) | 0.001 |
| Severe | 1 (2%) | 1 (4%) | 0.001 |
| Pregnancy (Chemical & Clinical) | 10 (23.3%) | 7 (36.0%) | 0.13 |
| Abortion | 3 (6.0%) | 4 (16.0%) | 0.21 |
| Multifetal pregnancy | 0 | 0 | 1 |
| Drug complication | 0 | 0 | 1 |
Values are presented as mean±SD or frequency (percent). HCG; human chorionic gonadotropin; MII oocytes; metaphase II oocytes, ART; assisted reproduction treatment, OHSS; ovarian hyperstimulation syndrome. ZIFT; zygote intrafallopian transfer